Skip to main content

Table 2 Toxicity during the course of chemoradiation

From: A phase II trial of neoadjuvant IMRT-based chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma

 

Grade 1

Grade 2

Grade 3

n

%

n

%

n

%

Diarrhea

15

35.71%

12

28.57%

5

11.90%

Hematologic

8

19.05%

8

19.05%

1

2.38%

Fatigue

8

19.05%

5

11.90%

3

7.14%

Radiation dermatitis

5

11.90%

18

42.86%

9

21.43%

Neurosensory

1

2.38%

1

2.38%

1

2.38%

Hand-foot syndrome

2

4.76%

0

0.00%

0

0.00%